Table 1.

Participant characteristics (N = 203)

	Overall population	With symptom cluster	Without symptom cluster
Mean age (SD)	60.5 (8.5) yr	60.1 (9.4) yr	60.6 (8.3) yr
Body mass index (kg/m2)
Normal weight (18.5–24.9)	83 (41.1 %)	9 (26.5 %)	74 (44 %)
Overweight (25–29.9)	59 (29.2 %)	12 (35.3 %)	47 (28 %)
Obese (>30)	60 (29.7 %)	13 (38.2 %)	47 (28 %)
Race
White	163 (80.7 %)	26 (76.5 %)	137 (81.5 %)
Non-white	39 (19.3 %)	8 (23.5 %)	31 (18.5 %)
Education
High school or less	46 (22.8 %)	8 (23.5 %)	38 (22.6 %)
College	93 (46 %)	20 (58.8 %)	73 (43.5 %)
Graduate/professional	63 (31.2 %)	6 (17.7 %)	57 (33.9 %)
Years since LMP
<5 yr	41 (21.5 %)	13 (40.6 %)	80 (50.3 %)
5–10 yr	57 (29.8 %)	10 (31.3 %)	47 (29.6 %)
>10 yr	93 (48.7 %)	9 (28.1 %)	32 (20.1 %)
Cancer stage
Stage 0/I	94 (47 %)	13 (38.2 %)	81 (48.8 %)
Stage II	81 (40.5 %)	16 (47.1 %)	65 (39.2 %)
Stage III	25 (12.5 %)	5 (14.7 %)	20 (12 %)
AI taken
Anastrozole	148 (74.4 %)	27 (79.4 %)	121 (73.3 %)
Exemestane	20 (10 %)	2 (5.9 %)	18 (10.9 %)
Letrozole	31 (15.6 %)	5 (14.7 %)	26 (15.8 %)
Years on AI
<1 yr	54 (26.7 %)	11 (32.4 %)	43 (25.6 %)
1–3 yr	85 (42.1 %)	12 (35.3 %)	73 (43.5 %)
>3 yr	63 (31.2 %)	11 (32.3 %)	52 (30.9 %)
Chemotherapy history
None	77 (38.3 %)	14 (41.2 %)	63 (37.7 %)
Regimen with a taxane	78 (38.8 %)	10 (29.4 %)	36 (21.6 %)
Regimen without a taxane	46 (22.9 %)	10 (29.4 %)	68 (40.7 %)
NSAID use in last 7 days
Yes	61 (30.3 %)	17 (50 %)	44 (26.3 %)
No	138 (68.7 %)	17 (50 %)	121 (72.5 %)
Don’t know	2 (1 %)	0 (0 %)	2 (1.2 %)

AI aromatase inhibitor, LMP last menstrual period, NSAID non-steroidal anti-inflammatory drug, SD standard deviation

Symptom cluster refers to comorbid arthralgia, fatigue, and insomnia